Skip to main
PSNL
PSNL logo

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 70%
Buy 10%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc. demonstrated a positive financial trajectory with a notable increase in gross margin, reaching 27.1% in 4Q24, which reflects a 50 basis points year-over-year improvement, driven by a favorable customer mix and increased biopharma volume. Revenue from biopharma testing and services surged by 59% to $51 million in 2024, underscoring strong demand and effective partnerships, particularly with Tempus. Furthermore, substantial growth in clinical test volumes by 53% in 2Q24 and 4Q24 illustrates the company's expanding market presence and its commitment to enhancing commercial capabilities ahead of anticipated reimbursement developments.

Bears say

Personalis Inc. reported a decline in operating expenses for 4Q24, yet this decrease does not offset the concerning drop in revenue, which decreased by 15% year-over-year, indicating potential issues in demand for its genomic sequencing services. The company's revenue from its VA MVP partnership saw a significant decline from $4.4 million in 3Q24 to only $0.2 million in 4Q24, highlighting a critical risk in maintaining essential contracts and revenue streams. Furthermore, the projected total revenues for 2025 have been revised downward to $86.9 million, a significant drop from prior estimates, signaling challenges in both biopharma customer adoption of new products and overall market growth in the clinical diagnostics sector.

Personalis Inc (PSNL) has been analyzed by 10 analysts, with a consensus rating of Buy. 70% of analysts recommend a Strong Buy, 10% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Buy based on their latest research and market trends.

According to 10 analysts, Personalis Inc (PSNL) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.